Showing results (561-570 of 712) with videos related to

Sort By:
Pageof 72
Archives of Environmental Contamination and Toxicology|March 8, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part III. Effluent toxicity testsF J Dwyer, D K Hardesty, C E Henke, et al.
Circulation|November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery diseaseK Robinson, E L Mayer, D P Miller, et al.
Annals of Surgical Oncology|September 5, 2023
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical TrialCharity C Glass, Robert M Pride, Rachel A Freedman, et al.
Breast Cancer Research and Treatment|August 4, 2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trialKate Lloyd, Lisa A Newman, Charity Glass, et al.
The Oncologist|December 20, 2024
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancerShadab A Rahman, Hanneke Poort, Deborah Schrag, et al.
The American Journal of Gastroenterology|April 24, 2001
The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset diseaseP N Akolkar, B Gulwani-Akolkar, X Y Lin, et al.
Neurology|August 20, 2017
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adultsGe Li, Cynthia L Mayer, Daniel Morelli, et al.
Nature|June 7, 2023
Cryo-EM structure of SARS-CoV-2 postfusion spike in membraneWei Shi, Yongfei Cai, Haisun Zhu, et al.
Clinical Breast Cancer|September 11, 2014
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancerErica L Mayer, Adrienne B Gropper, Lyndsay Harris, et al.
Breast Cancer Research and Treatment|July 23, 2013
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancerErica L Mayer, M E Scheulen, J Beckman, et al.
Pageof 72